1. Home
  2. RIGL vs NAN Comparison

RIGL vs NAN Comparison

Compare RIGL & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • NAN
  • Stock Information
  • Founded
  • RIGL 1996
  • NAN 1999
  • Country
  • RIGL United States
  • NAN United States
  • Employees
  • RIGL N/A
  • NAN N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • NAN Investment Managers
  • Sector
  • RIGL Health Care
  • NAN Finance
  • Exchange
  • RIGL Nasdaq
  • NAN Nasdaq
  • Market Cap
  • RIGL 335.5M
  • NAN 347.2M
  • IPO Year
  • RIGL 2000
  • NAN N/A
  • Fundamental
  • Price
  • RIGL $20.97
  • NAN $11.31
  • Analyst Decision
  • RIGL Buy
  • NAN
  • Analyst Count
  • RIGL 5
  • NAN 0
  • Target Price
  • RIGL $36.40
  • NAN N/A
  • AVG Volume (30 Days)
  • RIGL 217.1K
  • NAN 74.6K
  • Earning Date
  • RIGL 08-05-2025
  • NAN 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • NAN 4.37%
  • EPS Growth
  • RIGL N/A
  • NAN N/A
  • EPS
  • RIGL 2.08
  • NAN N/A
  • Revenue
  • RIGL $203,077,000.00
  • NAN N/A
  • Revenue This Year
  • RIGL $14.41
  • NAN N/A
  • Revenue Next Year
  • RIGL $15.97
  • NAN N/A
  • P/E Ratio
  • RIGL $10.14
  • NAN N/A
  • Revenue Growth
  • RIGL 70.16
  • NAN N/A
  • 52 Week Low
  • RIGL $7.48
  • NAN $9.11
  • 52 Week High
  • RIGL $29.82
  • NAN $11.34
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 61.71
  • NAN 53.35
  • Support Level
  • RIGL $18.63
  • NAN $11.25
  • Resistance Level
  • RIGL $20.99
  • NAN $11.38
  • Average True Range (ATR)
  • RIGL 1.07
  • NAN 0.10
  • MACD
  • RIGL 0.11
  • NAN 0.01
  • Stochastic Oscillator
  • RIGL 82.81
  • NAN 73.08

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: